PRİMER SJÖGREN SENDROMLU HASTALARDA ROMA IV FONKSİYONEL BARSAK HASTALIKLARI TANI KRİTERLERİ IŞIĞINDA FONKSİYONEL BARSAK HASTALIĞI SIKLIĞI

Amaç: Sjögren Sendromu (SS), kserostomi ve kseroftalmi ile kendini gösteren etyopatogenezinde özelliklelenfositlerin rol oynadığı kadın egemen bir hastalıktır. Bu çalışmamızda Primer SS (PSS)’lu hastalarda Roma IVkriterleri ile fonksiyonel barsak hastalığı (FBH) sıklığı araştırılmak istenmiştir.Materyal ve Metot: Haziran 2018 – Eylül 2019 arasında Kayseri Şehir Hastanesi Romatoloji Polikliniklerinebaşvuran ve 2016 ACR/EULAR PSS sınıflandırma kriterleri uyarınca PSS olarak sınıflandırılan 52 hastaçalışmaya alındı. FBH açısından sorgulanan ve son altı ay içinde %10 dan fazla kilo kaybı, dışkılamaalışkanlığında eskiye oranla yeni değişiklik, ailede erken yaş intestinal malignite varlığı, bulantı kusma ve akutbatın bulguları olan kişiler alarm semptomu/organik patoloji olasılığı sebebiyle çalışmaya alınmadı. Kontrolgrubu olarak da Hematoloji Polikliniğine başvuran hastaların yakınları, yaş ve cinsiyet gözetilerek seçildi.Anket kullanılarak yapılan sorgulamalar neticesinde FBH varlığı ve var olan FBH tipi not edildi ve PSS’luhastalarda ve sağlıklı kontrollerde görülme oranları % olarak belirtildi.Bulgular: PSS hastalarında 24/52 (%46,15) hastada FBH varken sağlıklı kontrollerin 17/75 (%22,66) hastadaFBH saptandı [p

PREVALENCE OF FUNCTIONAL BOWEL DISEASE IN THE LIGHT OF DIAGNOSTIC CRITERIA OF ROME IV FUNCTIONAL BOWEL DISEASES IN PATIENTS WITH PRIMARY SJOGREN SYNDROME

Objectives: Sjogren's Syndrome (SS) is a female-dominated disease in which lymphocytes play a critical role in the etiopathogenesis and manifest by xerostomia and xerophthalmia. In this study, we aimed to investigate the frequency of functional bowel disease (FBD) according to Roma IV criteria in patients with primary SS (PSS). Materials and Methods: 52 patients who admitted to Kayseri City Hospital Rheumatology Polyclinics between June 2018 - September 2019 and classified as PSS according to 2016 ACR / EULAR PSS classification criteria were included in the study. Subjects were questioned about FBD, and who had more than 10% weight loss in the last six months, new changes in defecation habits, presence of early age intestinal malignancy in his family history, nausea/vomiting and acute abdominal findings were excluded due to the possibility of alarm symptoms/organic pathology. The control group was the relatives of the patients who applied to the Hematology Outpatient Clinic, and they were selected according to age and gender. Inquiries were made using a questionnaire, the presence of FBD and the type of FBD were noted, and the incidence rate in patients with PSS and healthy controls was reported as a percent. Results: In PSS patients, 24/52 (46.15%) patients had FBD and 17/75 (22.67%) healthy controls had FBD [p

PDF

___

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21
2. Çelebi S, Açık Y, Deveci SE ve ark. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol 2004;19:738-43.
3. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:1262–79.
4. Karaman N, Türkay C, Yönem Ö. Irritable bowel syndrome prevalence in city center of Sivas. Turk J Gastroenterol 2003;14:128-31.
5. Akpınar H, Kılıç B, Amanvermez D. Prevalence of irritable bowel syndrome in İzmir Narlıdere region. Turk J Gastroenterol 1999;10 (Suppl.2):21.
6. Yılmaz Ş, Dursun M, Ertem M,Canoruc F, Turhanoğlu A. The epidemiological aspects of irritable bowel syndrome in Southeastern Anatolia: a stratified randomised community-based study. Int J Clin Pract 2005;59: 361-9
7. Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD ve ark. Chronic constipation. Nat Rev Dis Primers. 2017 Dec 14;3:17095. (doi: 10.1038/nrdp.2017.95)
8. Erbasan F, Cekin Y, Coban DT, Karasu U, Suren D, Cekin AH. The Frequency of Primary Sjogren’s Syndrome and Fibromyalgia in Irritable Bowel Syndrome. Pak J Med Sci. 2017;33(1):137-41. (doi: https://doi.org/10.12669/pjms.331.11168).
9. Özden A, Köksal AŞ, Oğuz D ve ark. Türkiye’de birinci basamak sağlık kurumlarında irritabl barsak sendromu görülme sıklığı. Akademik Gastroenteroloji Dergisi, 2006;5(1):4-15
10. Giorgio R, Barbara G, Stanghellini V ve ark. Diagnosis and therapy of irritable bowel syndrome. Aliment Phramacol Ther 2004;20 (Suppl 2):10-22
11. Popov Y, Salomon-Escoto K. Gastrointestinal and Hepatic Disease in Sjogren Syndrome. Rheum Dis Clin North Am. 2018 Feb;44(1):143-51. (doi: 10.1016/j.rdc.2017.09.010).
12. Sarac O, Kosekahya P, Yildiz Tasci Y, Keklikoglu HD, Deniz O, Erten ve ark. The Prevalence of Dry Eye and Sjögren Syndrome in Patients with Migraine. Ocul Immunol Inflamm. 2017 Jun;25(3):370-5. (doi: 10.3109/09273948.2015.1132739).
13. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 2016 Jul 1;1(1):154-65. (doi: 10.1089/can.2016.0009).
14. de Oliveira FR, Fantucci MZ, Adriano L ve ark. Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway. Int. J. Mol. Sci. 2018;19:3953. (doi:10.3390/ijms19123953).